FRONTEO Obtains Patent Approval in Korea for "Conversational Dementia Diagnosis Support AI Program"

2021.08.19 Press release

--To the press -

FRONTEO Obtains Patent Approval in Korea for "Conversational Dementia Diagnosis Support AI Program"

FRONTEO Inc.
Masahiro Morimoto, President and CEO
2-12-23 Konan, Minato-ku, Tokyo
(Code number: 2158 TSE Mothers)

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) has applied for an international patent on the "Conversational Dementia Diagnosis Support AI Program". We are pleased to inform you that we have received a notice of patent decision (application number: Japanese Patent Application No. 10-2020-7037398 / registration number not given) from the Patent Office.Following Japan, this program is the second country to be granted patentability.

 

 The "Conversational Dementia Diagnosis Support AI Program" uses FRONTEO's natural language analysis AI engine "Concept Encoder (trademark: concept encoder, reading: concept encoder)" to screen for the presence or absence of dementia from natural conversation for about 10 minutes. This is an epoch-making program.As the world ages and medical costs related to dementia increase year by year, we are proceeding with development with the aim of improving the prognosis by early detection of dementia, reducing the burden of dementia diagnosis, and utilizing it as a new digital biomarker. In July 2020, we obtained a patent right from the Japanese Patent Office (patent registration number: Patent No. 7).

 

 This program started clinical trials in April 2021 and is currently working toward obtaining manufacturing and marketing approval in Japan and early launch.We believe that the acquisition of a patent grant in South Korea is an important step in expanding this system to overseas markets.

 

 According to a report by the International Association for Alzheimer's Disease, the number of Alzheimer's disease patients worldwide is estimated to reach about 2050 million in 2020, which is about 2.6 times that of 1.1), It can be said that measures against dementia are important issues not only in Japan but also in the world. FRONTEO will continue to contribute to solving various medical and social issues associated with the aging of the population through research and development and commercialization of its own AI technology.

 

1) Alzheimer's Disease International: Estimated numbers of people with dementia by region (millions),
  https://www.alzint.org/u/numbers-people-with-dementia-2017.pdf

 


■ About conversational dementia diagnosis support AI program

URL:https://lifescience.fronteo.com/aidevice/dementia/
The "Conversational Dementia Diagnosis Support Program" (AI medical device) uses FRONTEO's original natural language analysis AI "Concept Encoder" to enable cognitive dysfunction from daily conversation between a doctor and a patient for about 5 to 10 minutes. It is a system that can screen. FRONTEO believes that this system can contribute to the progress of digital medical care such as telemedicine and the efficiency and standardization of medical care, in addition to measures against dementia, which is an important issue in Japan, which has entered a super-aging society. I am. We started clinical trials in April 2021 and are currently working toward early manufacturing and marketing approval and early launch.Patent registration number: Patent No. 4

■ About Concept Encoder
URL:https://lifescience.fronteo.com/technology/conceptencoder/
"Concept Encoder" is a natural language analysis AI (artificial intelligence) developed by FRONTEO specially in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. Concept Encoder can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals, and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

■ About FRONTEO URL:https://www.fronteo.com/
FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, focusing on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and economic security from 8, and by using AI to "turn text data into knowledge" , Drug discovery support, dementia diagnosis support, financial / human resources / sales support, etc., contributing to solving various corporate issues. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, conceptencoder, and KIBIT are registered trademarks of FRONTEO in Japan.

<Contact information for the press>

Public Relations Officer, FRONTEO Inc. Segawa

Email: pr_contact@fronteo.com

 

<Inquiries about Life Science AI Business>

FRONTEO Inc. Life Science AI Business Headquarters

https://lifescience.fronteo.com/contact

ja 日本語
Machine Translation by Google. : close x